

PG3602USW

disease, Pick's disease, Huntington's chorea, Parkinson's disease, Creutzfeldt-Jakob disease, vascular dementia, multi-infarct dementia, dementia associated with intracranial space occupying lesions, trauma, infections, metabolism, toxins, anoxia, and vitamin deficiency; and mild cognitive impairment associated with aging.

33. (New) The method of claim 31, wherein said cognitive disorder is dementia.
34. (New) The method of claim 31, wherein said cognitive disorder is Alzheimer's disease.
35. (New) 4-[2-(3-fluoro-phenyl)-6-trifluoromethyl-pyrazolo[1,5-a]pyridin-3-yl]-benzenesulfonamide.

Remarks

Currently Claims 1-10, 13-14 and 17-35 are pending. Applicants acknowledge with appreciation the Examiner's Indication that claims 6-10, 17 and 35 are allowed. Claims 1-5 are amended as discussed below.

Applicants acknowledge with appreciation the Examiner's grant of the telephonic interview of 20 February 2002. During this interview, Applicants previously filed traversal of the restriction requirement and the status of the remaining elected claims, i.e., claims 13, 24 and 26-29, was clarified. The Examiner has agreed that claims 13, 24 and 26-29 should have been examined and that these claims will be examined in the instant case following the filing of this response. The Examiner also confirmed that examination of the remaining, previously non-elected, process and method of use claims will proceed in the event that a compound claim of the same scope is allowed.

Claims 1-5 currently stand rejected under 35 U.S.C. section 112, the office action stating that the claims are indefinite. Claims 1-5 have been amended to remove the term "compounds" and substitute therefor the phrase "a compound," as suggested by the Examiner. It is respectfully submitted that this rejection is overcome.

PG3602USW

Inasmuch as the foregoing amendment places claim 1 in allowable form, Applicants respectfully request that examination now proceed for all pending claims.

Applicants note the return of the initial PTO Form-1449 wherein the Examiner has crossed off the Foreign Patent References and Other Documents that were submitted with the IDS mailed 28 September 2001. During the telephone interview, the Examiner indicated that the references were crossed off because copies of such references were not received by the Examiner. Applicants respectfully submit that copies of all references were provided with the IDS and enclose herewith the stamped postcard which indicates that the 21 cited references were received by the Office. Applicants enclose herewith a copy of the IDS and PTO Form 1449 mailed 28 September 2001 along with duplicate copies of the references not received by the Examiner and respectfully request consideration of these references in connection with the examination of all pending claims and return of the initialed PTO Form-1449. No fee is due inasmuch as the IDS was timely filed before the mailing of the first Office Action in this case. The Examiner is respectfully requested to contact Applicants' Attorney by phone if copies of the provided documents are not received so that Applicants may promptly provide additional copies directly to the Examiner.

Applicants respectfully request that the Examiner take notice of the following co-pending patent applications:

U.S. Patent Application Serial No.	Filing Date
09/508,029	3 Sep 98
09/890,925	22 Dec 99
10/001,600	31 Oct 01

PG3602USW

Applicants respectfully submit that the instant application is in condition for allowance, which action is respectfully requested. The Examiner is invited to contact the undersigned at 483-8222, to discuss this case further if desired.

Respectfully submitted,




Lorie Ann Morgan
Attorney for Applicants
Registration No. 38,181

Date: 21 February, 2002
GlaxoSmithKline
Five Moore Drive, PO Box 13398
Research Triangle Park
North Carolina 27709
(919) 483-8222
fax: (919) 483-7988

PG3602USW

Marked-up Claims

1. (Twice Amended) A compound [Compounds] of formula (I)



and pharmaceutically acceptable derivatives thereof wherein

R^0 and R^1 are independently selected from the group consisting of H, halogen, C_1 -alkyl, C_1 -alkoxy, and C_1 -alkoxy substituted by one or more fluorine atoms;

R^2 is selected from the group consisting of H, C_1 -alkyl, C_1 -alkyl substituted by one or more fluorine atoms, C_1 -alkoxy, C_1 -hydroxyalkyl, SC_1 -alkyl, $C(O)H$, $C(O)C_1$ -alkyl, C_1 -alkylsulphonyl, and C_1 -alkoxy substituted by one or more fluorine atoms; and

R^3 is C_1 -alkyl or NH_2 .

2. (Twice Amended) A compound [Compounds] as claimed in claim 1 wherein R^0 and R^1 are independently selected from the group consisting of H, halogen, C_1 -alkyl, and C_1 -alkoxy; R^2 is C_1 -alkyl substituted by one or more fluorine atoms; and R^3 is C_1 -alkyl or NH_2 .

3. (Twice Amended) A compound [Compounds] as claimed in claim 1 wherein R^0 and R^1 are independently selected from the group consisting of H, F, Cl, C_1 -alkyl, and C_1 -alkoxy; R^2 is C_1 -alkyl substituted by one or more fluorine atoms; and R^3 is methyl or NH_2 .

PG3602USW

Marked-up Claims

4. (Twice Amended) A compound [Compounds] as claimed in claim 1 wherein R^0 is selected from the group consisting of F, Cl, C_{1-3} alkyl and C_{1-3} alkoxy; R^1 is H; R^2 is C_{1-3} alkyl substituted by one or more fluorine atoms; and R^3 is methyl or NH_2 .
5. (Twice Amended) A compound [Compounds] as claimed in claim 1 wherein R^0 is at the 3- or 4- position of the phenyl ring; and R^2 is at the 6- position of the pyridine ring.